nature portfolio

Corresponding author(s):	Mathieu Blanchette
Last updated by author(s):	Nov 10, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

\sim		100		
⋖.	トつ	11	IST.	ICC
.)	ıa		וכו	115

For	ali st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	nfirmed
x		The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	×	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
X		A description of all covariates tested
x		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
×		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	×	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
X		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
X		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
×		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

We downloaded ChIP-Seq data from ENCODE (https://www.encodeproject.org/), UCSC Genome Browser (https://genome.ucsc.edu/), and 4DN Data Portal (https://data.4dnucleome.org/) with wget and curl.

Data analysis

The software in this manuscript is publicly available at https://github.com/BlanchetteLab/RefHiC, and instructions for reproducing all the results in the manuscript are at https://zenodo.org/record/7133194. It relies on cooler (0.8.11), PyTorch (1.11.0), NumPy (1.19.5), matplotlib (3.3.4), einops (0.3.2),appdirs (1.4.4), click (8.0.1), pandas (1.3.5)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data analyzed during this study are included in this published article (and its supplementary information files): All data included in the reference panels of this study are summarized in Supplementary Tables 1, 2, and 3 with references and/or accession codes. They are all publicly available at GEO, ENCODE or 4DN data

		anchem/RefHiC. We trained and evaluated RefHiC using public available contact maps including GM12878 90 (4DNFIJTOIGOI), HCT-116 (4DNFILP99QJS), mESC (4DNFIDA2WGV8).	
(12111111111111111111111111111111111111	· <u>·</u> · · · · · · · · · · · · · · · · · ·		
Human resea	arch participant		
Policy information a	bout studies involving h	numan research participants and Sex and Gender in Research.	
Reporting on sex and gender This study does no		y does not involve human research participants.	
		y does not involve human research participants.	
Recruitment This study does no		y does not involve human research participants.	
Ethics oversight	This stud	y does not involve human research participants.	
Note that full informat	tion on the approval of the	study protocol must also be provided in the manuscript.	
Field-spe	cific report	ing	
Please select the on	e below that is the best	fit for your research. If you are not sure, read the appropriate sections before making your selection.	
x Life sciences	Behaviour	al & social sciences	
or a reference copy of th	ne document with all sections,	see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>	
<u>_ife scien</u>	ces study o	design	
All studies must disc	close on these points ev	en when the disclosure is negative.	
Sample size	We do not need to deterr	nine the sample size in this study.	
Data exclusions	No data were excluded fro	om the analysis.	
Replication	Our software is open source and was tested on major Unix-like operating systems. We performed TAD and loop detections from different Hi-C data of different sequence depths and confirmed the reproducibility and provided results in Figure 4, Suppl. Figures 4, 10, and 11.		
Randomization	This is not relevant to our	study. Our study does not involve any experimental group allocations.	
Blinding	This is not relevant to our	study. Our study does not involve any group allocations.	
O	- f : : : : : : : : : : : : : : :		
		ic materials, systems and methods	
		e types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, /. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.	
Matariala O avra		N d a than a d a	
, I	erimental systems	Methods n/a Involved in the study	
n/a Involved in the study Antibodies		X ChIP-seq	
Eukaryotic cell lines		Flow cytometry	
		MRI-based neuroimaging	
Animals and	d other organisms	'	
Clinical data	3		
Dual use res	search of concern		